Also trades as: PLX.TA (TLV) · $vol 0M
PLX AMEX
Protalix BioTherapeutics, Inc.
1W: -0.4%
1M: +4.6%
3M: +17.8%
YTD: +55.8%
1Y: +14.8%
3Y: +59.4%
5Y: +106.9%
$2.71
+0.03 (+1.12%)
Weekly Expected Move ±5.2%
$2
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2021-07-02
Earliest Filing
2025-08-22
Latest Filing
partner: 6
Counterparties (Filed by PLX)
6 relationshipsCompanies named in PLX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| H.C. Wainwright & Co., LLC | — | partner | Sales agent for the Company's at-the-market equity offering program. | 2025-08-22 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent for the Company's at-the-market equity offering program | 2025-03-17 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent for At The Market Offering Agreement | 2023-02-27 | View |
| Chiesi Farmaceutici S.p.A. | — | partner | Entered into a Fill/Finish Agreement and Letter Agreement to serve as commercialization partner for PRX-102. | 2022-09-01 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent for the Company's At The Market Offering Agreement. | 2022-05-02 | View |
| H.C. Wainwright & Co., LLC | — | partner | Entered into an At The Market Offering Agreement to act as sales agent for the Company's common stock. | 2021-07-02 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-06-25 | Shareholder Vote; Exhibits | View | |
| 2026-05-21 | Regulation FD; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-03-09 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-30 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-05 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-17 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-22 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-01 | Other Events | View | |
| 2025-07-21 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-06-26 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-23 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-03-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-17 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR